Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphomaANNALS OF HEMATOLOGYIF2.42021-02-0212PREAI
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin LymphomaHEMASPHEREIF14.62020-09-2318OAAI
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy FailureHEMASPHEREIF14.62020-06-0818OAAI